Back to Results
First PageMeta Content
Immunosuppressants / Orphan drugs / Amides / Bortezomib / Pyrazines / Lenalidomide / Multiple myeloma / Dexamethasone / Mantle cell lymphoma / Medicine / Chemistry / Organic chemistry


ASCO[removed]Clinical response by baseline characteristics in patients with relapsed and bortezomib-refractory multiple myeloma treated with panobinostat, bortezomib, and dexamethasone (PANORAMA 2) Melissa Alsina,1 Paul G.
Add to Reading List

Document Date: 2013-06-10 19:40:25

Open Document

File Size: 408,41 KB

Share Result on Facebook

City

Houston / Tampa / Hanover / Palo Alto / Durham / /

Company

IgG / 6Novartis Pharmaceuticals / AEs / International Myeloma Working Group / Cancer Therapy/Gynecologic Oncology Group / 3M / Eastern Cooperative Oncology Group / /

Country

United States / /

Currency

pence / /

Facility

Research Institute / 7Winship Cancer Institute / Farber Cancer Institute / University Medical Center / Anderson Cancer Center / University School / Harvard University / Emory University / /

IndustryTerm

Cancer Therapy / /

MedicalCondition

Leukemia / pneumonia / Measurable disease / Cancer / Multiple myeloma / Disease / Peripheral neuropathy symptoms / relapsed and bortezomib-refractory multiple myeloma / progressive disease / incurable disease / neutropenia / nausea / thrombocytopenia / Peripheral neuropathy / soft tissue plasmacytomas / fatigue / diarrhea / anemia / Primary refractory disease / /

Organization

Research Institute / 5Duke University Medical Center / 2Dana-Farber Cancer Institute / 4Stanford University School of Medicine / 7Winship Cancer Institute / Lee Moffitt Cancer Center / Emory University / Atlanta / Anderson Cancer Center / Harvard University / Boston / /

Person

Melissa Alsina / Lee Moffitt / /

Product

dexamethasone / /

ProvinceOrState

Texas / New Jersey / Florida / California / Georgia / Massachusetts / /

Technology

hybridization / Transplantation / /

SocialTag